Corindus Vascular Robotics (CVRS) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corindus Vascular Robotics (CVRS) PT Lowered to $1.75 at Cowen; Reiterates Outperform
November 8, 2017 8:09 AM ESTCowen lowered its price target on Corindus Vascular Robotics (NYSE: CVRS) to $1.75 (from $2.50) while maintaining a Outperform rating.
Corindus experienced continued clinician interest in the next gen CorPath GRX system but the revenue performance was limited by an unpredictable sales cycle. Management... More
